tbuckley/cabot-search huggingface dataset:
Parotidite epidémica em Portugal apesar duma elevada cobertura vacinal - relatório preliminar
Authors: J A Dias, M Cordeiro, M A Afzal, M G Freitas, M. R. Morgado, J. L. Silva, L. M. Nunes, M. G. Lima, F Avilez
Journal: Eurosurveillance (1996)

Em Portugal a vacina trivalente de sarampo, parotidite epidemica e rubeola (VASPR) foi incluida no Programa Nacional de Vacinacao (PNV) em 1987. Todas as vacinas sao gratuitas nos Centros de Saude. Em 1995 teve inicio na regiao norte um surto de parotidite epidemica que depois se estendeu a todo o pais.
Radioguided Occult Lesion Localization
Authors: Gianpiero Manca, Sara Mazzarri, Domenico Rubello, Elisa Tardelli, Roberto C. Delgado-Bolton, Francesco Giammarile, Manuela Roncella, Duccio Volterrani, Patrick M. Colletti
Journal: Clinical Nuclear Medicine (2017)

Regarding radioguided surgery, the concept of "radioguided occult lesion localization" (ROLL) is based on both preoperative interventional imaging and intraoperative radioguided detection of a clinically occult neoplastic lesion.This methodology consists in the direct administration into the lesion of Tc-macroaggregated human albumin formed by relatively large particles retained at the injection site, which direct radioguided excisional biopsy.This modality has expanded from the classic application of ROLL for nonpalpable breast lesions to other tumors, such as solitary pulmonary nodules or recurrences from differentiated thyroid carcinoma. In 2011, in order to improve the classification of different radioguided surgical procedures, ROLL applications were included in the more complete concept of GOSTT (Guided intraOperative Scintigraphic Tumor Targeting). This concept was introduced to include the entire range of basic and advanced radioguided procedures necessary to supply a "road map" for the surgeon.The terms ROLL and GOSTT have further developed by incorporating novel modalities such as hybrid tracers for simultaneous fluorescence and radioactive signal detection and innovative navigation systems based on mixed-reality protocols.
Do patients (pts) with advanced nonseminomatous germ cell tumors (aNSGCT) and unfavorable time to normalization (TTN) of tumor markers benefit with prolongation of 1-st line chemotherapy (ChT)?
Authors: A. Tryakin, M. Fedyanin, J. Sergeev, A. Bulanov, B. Akhmedov, T. Zakharova, V. Matveev, I. Fainstein, A. Garin, S. Tjulandin
Journal: Annals of Oncology (2017)
Low Bleeding Rates with Increase or Maintenance of Physical Activity in Patients Treated with Recombinant Factor IX Fc Fusion Protein (rFIXFc) in the B-LONG and Kids B-LONG Studies
Authors: Roshni Kulkarni, Amy D Shapiro, Jerzy Windyga, Margaret V Ragni, K John Pasi, Margareth Castro Ozelo, Elisa Tsao, Baisong Mei
Journal: Blood (2015)
Nivolumab, ipilimumab and COX2-inhibition in early stage colon cancer
Authors: M. Chalabi, M. Van Leerdam, A. Aalbers, J. Van den Berg, G. Beets, C. Grootscholten, P. Snaebjornsson, M. Kuiper, P. Den Hartog, F. Weeber, K. Dijkstra, M. Kok, D. Cullen, T.N.M. Schumacher, J.B. Haanen, E. Voest
Journal: Annals of Oncology (2017)
Raltitrexed versus 5-fluorouracil with cisplatin and concurrent radiotherapy (CCRT) for locally advanced head and neck squamous cell carcinoma (LA-HNSCC): A randomized controlled multi-centered trial
Authors: X. He, H. Yin, W. Guo, X. Sun, X. Hu, P. Yan, F. Li, S. Huang, H. Zhou, F. Zhang, B. Wang, X. Bian, Q. Wei, J. Wu, F. Wang, D. Song, J. Liu, B. Zhou
Journal: Annals of Oncology (2017)
Endoscopic ultrasound: A safe procedure for elderly oncology patients?
Authors: Elizabeth S. John, Hadi Razjouyan, Nakul Singhal, Sita Chokhavatia, Amy Tilara
Journal: Journal of Clinical Oncology (2017)

e21531 Background: Endoscopic ultrasound (EUS) has many indications in the management of gastrointestinal tumors, and has become pivotal in guiding therapy. While studies show that surgery in the elderly with malignancy causes increased morbidity and costs, no studies exist to assess the safety of EUS in this group. Methods: A single center retrospective analysis of patients who underwent EUS by two advanced endoscopists from April 2015 to December 2015 was performed. Patient demographics, procedure indications, final diagnoses, procedure length, sedation type, ASA classification, and intra-procedural complications, peri-procedural (immediate) complications, and post-procedural (24 hours after) complications were collected. Statistical analysis was done with Chi-square and comparison of mean tests. Results: 111 patients were identified with either a confirmed or suspected gastrointestinal malignancy out of 200 total patients included in the study. These patients included 38 with suspected pancreatic adenocarcinoma, one of which revealed pancreatic gastrinoma; 27 with suspected gastric adenocarcinoma or for staging; 17 with suspicious esophageal masses or for staging of squamous cell carcinoma or adenocarcinoma; 9 duodenal masses, 3 colorectal masses, 2 mediastinal masses, 1 biliary mass, 3 potential metastatic lesions to the GI system, and 8 patients with abdominal lymphadenopathy suspicious for malignancy. Patients over 65 years tended to have a lower risk of intra-procedure complications compared to those under 65, irrespective of all other factors including gender, performing endoscopist, and length of procedure (8.3% vs. 18.3%, p = 0.09). No significant differences were found in peri- and post-procedural complications between the over age 65 and under age 65 groups (4.0% vs. 1.6%, p = 0.44; 5.9% vs. 15.2%, p = 0.19). Conclusions: Due to the poor performance status often seen in the elderly oncology population, complications often arise from invasive procedures leading to increased morbidity, mortality, and costs. EUS aids in diagnosis, staging, and therapeutic decision-making of patients with gastrointestinal malignancies, and as this study shows, can be performed in older patients without incurring increased risks.
Hdac3 regulates lymphovenous and lymphatic valve formation
Authors: Harish P. Janardhan, Zachary J. Milstone, Masahiro Shin, Nathan D. Lawson, John F. Keaney, Chinmay M. Trivedi
Journal: Journal of Clinical Investigation (2017)

Lymphedema, the most common lymphatic anomaly, involves defective lymphatic valve development; yet the epigenetic modifiers underlying lymphatic valve morphogenesis remain elusive. Here, we showed that during mouse development, the histone-modifying enzyme histone deacetylase 3 (Hdac3) regulates the formation of both lymphovenous valves, which maintain the separation of the blood and lymphatic vascular systems, and the lymphatic valves. Endothelium-specific ablation of Hdac3 in mice led to blood-filled lymphatic vessels, edema, defective lymphovenous valve morphogenesis, improper lymphatic drainage, defective lymphatic valve maturation, and complete lethality. Hdac3-deficient lymphovenous valves and lymphatic vessels exhibited reduced expression of the transcription factor Gata2 and its target genes. In response to oscillatory shear stress, the transcription factors Tal1, Gata2, and Ets1/2 physically interacted with and recruited Hdac3 to the evolutionarily conserved E-box–GATA–ETS composite element of a Gata2 intragenic enhancer. In turn, Hdac3 recruited histone acetyltransferase Ep300 to form an enhanceosome complex that promoted Gata2 expression. Together, these results identify Hdac3 as a key epigenetic modifier that maintains blood-lymph separation and integrates both extrinsic forces and intrinsic cues to regulate lymphatic valve development.
A large retrospective multicenter study evaluating prognosis and chemosensitivity of metastatic colorectal cancer with microsatellite instability
Authors: D. Tougeron, R. Cohen, B. Sueur, D. Sefrioui, L. Gentilhomme, T. Lecomte, T. Aparicio, G. Des Guetz, P. Artru, C. de la Fouchardiere, V. Moulin, V. Hautefeuille, R. Coriat, Y. Touchefeu, C. Lecaille, G. Goujon, A. Ferru, J. Taieb, T. André, A. Zaanan
Journal: Annals of Oncology (2017)
Vigilância da doença de Creutzfeldt-Jakob no Reino Unido
Authors: H J T Ward
Journal: Eurosurveillance (2000)

Ate ao fim de Maio de 2000, tinham sido notificados no Reino Unido 54 casos definitivos e 13 casos provaveis da nvDCJ pela National Creutzfeldt-Jakob Disease Surveillance Unit (Unidade Nacional de Vigilância da DCJ) formada em 1990. Todos os casos confirmados, dos quais existem dados disponiveis, sao homozigoticos para a metionina no codao 129 do gene da proteina do priao (PrP). Alem de realizar esta vigilância a nivel nacional, esta unidade participa em projectos de colaboracao, tais como o EUROCJD e NEUROCJD, financiados pela Uniao Europeia, os quais foram concebidos para efectuar comparacoes entre paises, constituindo um meio auxiliar para a identificacao de novos factores de risco.
Should We Screen This Patient for Carotid Artery Stenosis?
Authors: Gerald W. Smetana, Marc Schermerhorn, Kenneth J. Mukamal
Journal: Annals of Internal Medicine (2017)

In July 2014, the U.S. Preventive Services Task Force (USPSTF) published a clinical guideline on screening for asymptomatic carotid artery stenosis. The guideline recommended against screening in asymptomatic adults, based primarily on the results of 3 large randomized trials (grade D recommendation). The principal screening test was carotid ultrasonography, and the intervention in the 3 trials was carotid endarterectomy for patients with stenosis exceeding 50% to 60%. In a meta-analysis, carotid endarterectomy reduced rates of 1) perioperative stroke, death, or subsequent ipsilateral stroke and 2) perioperative stroke, death, or any subsequent stroke. The corresponding absolute risk differences were –2.0% (95% CI, –3.3% to –0.7%) and –3.5% (CI, –5.1% to –1.8%), respectively. However, perioperative stroke and death were substantially less common among the 3 randomized trials than in contemporaneous cohort studies (1.9% vs. 3.3%). In addition to stroke or death in patients receiving carotid endarterectomy, a harm of screening included the risk for angiography prompted by abnormal results on carotid ultrasonography. In this article, 2 discussants address the risks and benefits of screening for carotid artery disease as well as how to apply the guideline to an individual patient who is deciding whether to be screened.
Hope for salivary gland cancer (SGC): EORTC HNCG/UKCRN 1206 randomized phase II study to evaluate the efficacy and safety of Chemotherapy (CT) vs androgen deprivation therapy (ADT) in patients with recurrent and/or metastatic androgen receptor (AR) expressing SGC
Authors: L.D. Locati, C. Caballero, C. Fortpied, F. Perrone, S. Pilotti, K.J. Harrington, V. Grégoire, L. Licitra
Journal: Annals of Oncology (2017)
Functional genomic mRNA (FGmRNA) profiling of > 18,000 tumor samples identifies potential new indications for antibody-drug conjugates (ADCs) in a broad range of tumor types
Authors: K.L. Moek, D.J. de Groot, E.G.E. de Vries, R.S.N. Fehrmann
Journal: Annals of Oncology (2017)

Background: ADCs, consisting of an antibody designed against a specific antigen at the cell membrane linked with a cytotoxic agent, are an emerging class of therapeutics. Since ADC targets do not have to be drivers of tumor growth, ADCs are potentially relevant for a wide range of tumor types. Therefore, we aimed to define the landscape of ADC target expression in a broad range of tumor types. Methods: PubMed and ClinicalTrials.gov were searched for ADCs that are or were evaluated in clinical cancer trials. Gene expression profiles of 18,055 patient derived tumor samples representing 60 tumor (sub)types and ≥ 3,520 samples representing 22 healthy tissue types were collected from the public domain. Next, we applied FGmRNA-profiling (Fehrmann et al. Nat Genet 2015;47:115-25) to predict per tumor type the overexpression rate at the protein level of ADC targets with healthy tissue samples as reference. Results: We identified 87 ADCs directed against 59 unique targets. 17 ADC targets showed predicted overexpression of ≥ 75% of samples in at least 1 tumor (sub)type, 38 ≥ 50% and 56 ≥ 25%. A predicted overexpression rate of ≥ 10% of samples for multiple ADC targets was observed for high incidence tumors like breast cancer (n = 31 with n = 23 in triple negative breast cancer), colorectal cancer (n = 18), lung adenocarcinoma (n = 18), squamous cell lung cancer (n = 16) and prostate cancer (n = 5). In rare tumor types we identified targets showing high predicted overexpression, for example in uveal melanomas we found 95% predicted overexpression for c-MET. Conclusions: This study provides a data driven prioritisation of available ADCs for clinical evaluation in 60 tumor (sub)types. This comprehensive ADC target landscape can support clinicians and drug developers in trial design. Legal entity responsible for the study: UMCG Funding: European Research Council advanced grant OnQview to E.G.E. de Vries; the Dutch Cancer Society grant, the NWO-VENI grant and a Mandema Stipendium to R.S.N. Fehrmann Disclosure: E.G.E. de Vries: Advisory board: Medivation, Merck and Synthon: payments to the institution. Research grants: Amgen, Genentech/Roche, Chugai, Servier, Novartis, Synthon, AstraZeneca, Radius Health, CytomX, Nordic Nanovector: payments to the institution. All other authors have declared no conflicts of interest.
Febrile Neutropenia: a systematic review of the first 5 years of a cancer unit
Authors: J. Pinto, I. Leão, F. Branco, J. Godinho, P. Simões, F. Lopes, A. Escária, F. Costa, I. Galvão, J.L. Passos-Coelho
Journal: Annals of Oncology (2017)
Extended treatment with adjuvant imatinib (IM) for patients (pts) with high-risk primary gastrointestinal stromal tumor (GIST): The PERSIST-5 study.
Authors: Chandrajit P. Raut, N. Joseph Espat, Robert G. Maki, Dejka M. Araujo, Toni Faith Williams, Johannes E. Wolff, Ronald P. DeMatteo
Journal: Journal of Clinical Oncology (2017)

11009 Background: Adjuvant IM reduces risk of recurrence and improves survival in pts with high-risk primary GIST. Joensuu et al 2016 demonstrated higher 5-yr overall survival (OS) rates of 91.9% vs 85.3% in pts treated with adjuvant IM for 3 vs 1 yr, respectively. It is unknown if further extension of treatment duration can improve outcome. Methods: PERSIST-5 is a single-arm, phase II trial that enrolled pts ≥18 yrs of age, who underwent macroscopically complete resection of primary KIT (+) GIST with high risk of recurrence within 12 wks prior to IM treatment. High risk was defined as primary GIST (any site) ≥2 cm with a mitotic count ≥ 5/50 HPF or non-gastric primary GIST ≥5 cm. Pts were treated with IM 400 mg/d for 5 yrs or until progression, relapse, or intolerance. Primary endpoint was recurrence-free survival (RFS, defined as time of treatment start to first recurrence or death). Results: IM was administered to 91 pts with a median age of 60 yrs (range 30-90). Median tumor size was 6.5 cm (range 2.3-30 cm; 55% gastric origin). Median treatment duration was 55.7 mos (range, 0.5-75). Forty-six (50.5%) pts completed study treatment. The 5- and 8-yr estimated RFS rates were 90% (95% CI, 80-95) and 81% (95% CI, 62-91), respectively. The 5- and 8 year OS rate was 95% (95% CI, 86-99). There were 7 recurrences; 1 pt recurred and died while on IM ( PDGFRA D842V mutation) and 6 pts recurred after IM discontinuation. Two pts died after IM discontinuation, unrelated to study treatment and without recurrence. Forty-five pts discontinued study treatment; common reasons included patient choice (20%), adverse events (AEs, 17%), protocol deviation (4%), and loss of follow-up (4%). The most common AEs of all grades (regardless of relationship to IM) were nausea (71%), diarrhea (63%), fatigue (50%), muscle spasm (41%), vomiting (39%), and periorbital edema (34%). Conclusions: Five yrs of IM treatment was effective in preventing recurrence in pts with sensitive mutations who underwent resection of primary GIST. Nearly half of the patients discontinued treatment early, and most recurrences occurred after IM discontinuation. Clinical trial information: NCT00867113.
Cleopatra and Sour Milk—The Ancient Practice of Chemical Peeling
Authors: Susruthi Rajanala, Neelam A. Vashi
Journal: JAMA Dermatology (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
Gastroenteritis por SRSV-1 en Malta - 1995
Authors: D Falzon
Journal: Eurosurveillance (1996)

Se sabe que los virus pequenos de estructura redonda (SRSV) son causa de brotes de gastroenteritis en colectividades y que representan el 54% de los brotes persona a persona y el 6% de los brotes transmitidos por alimentos en Inglaterra y Gales (1). La infeccion se transmite generalmente de persona a persona y tambien por los alimentos, el agua y objetos contaminados. El periodo de incubacion es de 10 a 50 horas y el periodo de infeccion dura desde la fase aguda hasta 48 horas despues de haber desaparecido los sintomas (2). Este informe describe un gran brote de gastroenteritis por SRSV que tuvo lugar en un colegio privado de alumnado externo (colegio A) de Malta. El Servicio de Salud Publica de Malta recibio notificacion el 23 de noviembre de 1995 y realizo una investigacion para identificar el origen del brote y controlar su propagacion.
Paludismo de aeropuerto: cuatro nuevos casos en la periferia de París durante el verano de 1999
Authors: D Lusina, F Legros, V Estève, M Klerlein, T Giacomini
Journal: Eurosurveillance (2000)

Durante el verano de 1999, se identifico en Francia una nueva agrupacion de cuatro casos de paludismo de aeropuerto. El analisis de los casos revelo que el paludismo de aeropuerto, enfermedad poco frecuente y de diagnostico dificil, puede producirse incluso fuera de las profesiones de riesgo y en poblaciones con domicilio proximo a los aeropuertos. Este analisis tambien subraya la importancia de fumigar rigurosamente con insecticida todos los aviones procedentes de zonas paludicas, y la importancia que presentan los signos hematologicos indirectos del paludismo, especialmente la trombocitopenia.
NeuroCog-FX study: A multicenter cohort study on cognitive dysfunction in patients with early breast cancer
Authors: O. Rick, M. Reuß-Borst, T. Dauelsberg, H. Hass, V. König, R. Caspari, G. Götz-Keil, J. Pfitzner, C. Kerschgens, K. Fliessbach, C. Hoppe
Journal: Annals of Oncology (2017)
Abstract 19577: Incomplete Revascularization is Associated With an Increased Risk of Postoperative Myocardial Infarction Among Patients Undergoing Noncardiac Surgery
Authors: Javier A Valle, Ehrin J Armstrong, Laura Graham, Stephen W Waldo, Thomas M Maddox, Mary T Hawn
Journal: Circulation (2016)

Background:  Major adverse cardiac events remain a major source of morbidity after noncardiac surgery in patients with CAD. The impact of a complete revascularization strategy on MACE in these patients is unknown.   Methods:  We identified patients undergoing noncardiac surgeries within 2 years after PCI in VA hospitals from 2004-2012 and divided the cohort into patients with complete vs. incomplete revascularization. Incomplete revascularization was defined as a residual stenosis of ≥50% in the LMCA or ≥70% in another major epicardial coronary artery after PCI. We compared the association between incomplete revascularization and postoperative MACE (mortality, MI, revascularization), using multivariate logistic regression to adjust for demographic, clinical and procedural variables.   Results:  12,486 patients underwent noncardiac surgery within 2 years following PCI. Within the cohort, 4,332 (34.7%) patients had incomplete revascularization, and 567 had postoperative MACE. Patients with incomplete revascularization had a 5.0% rate of MACE, while those with complete revascularization had a rate of 4.3% (p=0.05). After multivariate adjustment, odds of MACE were not statistically significantly different between groups, however the odds of postoperative MI were significantly higher in patients with incomplete revascularization (OR 1.37, 95% CI 1.10-1.70;  Figure 1a ). Additionally, there was a significant interaction between time from PCI and postoperative MACE, with incomplete revascularization associated with an increased risk of postoperative MI if surgery was performed within six weeks after PCI (OR 1.84, 95% CI 1.04-2.38  Figure 1b ). Finally, for patients with incomplete revascularization, each unrevascularized vessel increased the odds of postoperative MI by 17%.   Conclusions:  Incomplete revascularization is associated with an increased risk of postoperative MI, especially if revascularization is performed within 6 weeks of surgery.
Internal Auditory Canal Tumor as an Incidental Finding on a Choline PET/CT Scan in a Prostate Cancer Patient
Authors: Julia Malamitsi, Roxanni Efthymiadou, Theodore Pipikos, Fani Vlachou, Vassilis Prassopoulos
Journal: Clinical Nuclear Medicine (2017)

An 84-year-old man with a history of prostate cancer, treated with radiotherapy, presented with an increase in PSA levels. F-choline PET/CT showed foci of increased choline uptake in L4 and L5 vertebrae, suggestive of bone metastases and another focus in the right cerebellopontine angle. A brain MRI revealed a focus of intense contrast enhancement in the same region, consistent with an acoustic neuroma.
Preparation of poly(lactide-co-glycolide) microspheres and evaluation of pharmacokinetics and tissue distribution of BDMC-PLGA-MS in rats
Authors: Guozhuan Li, Liang Yao, Jing Li, Xiaoyan Qin, Zhen Qiu, Weidong Chen
Journal: Asian Journal of Pharmaceutical Sciences (2017)

The aim of the present study was to develop a novel long-acting Poly (lactic-co-glycolic acid) (PLGA)-based microspheres formulation of Bisdemethoxycurcum (BDMC) by emulsion-solvent evaporation method. Meanwhile, the effects of the volume ratio of the dispersed phase and continuous phase, the concentration of PLGA and PVA, the theoretical drug loading and stirring speed were investigated. The mean diameter of the microspheres was 8.5 µm and the size distribution was narrow. The encapsulation efficiency (EE) and drug loading efficiency (DLE) of BDME loaded PLGA microspheres (BDMC-PLGA-MS) was 94.18% and 8.14%, respectively. In an in vitro study of drug release, it can be concluded that the BDMC-PLGA-MS exhibited sustained and long-term release properties for 96 h. Stability studies suggested that the microspheres we prepared had a very good stability. Furthermore, the results of an in vivo study indicated that the BDMC-PLGA-MS had sustained release effect and was mainly distributed in the lung tissue, and less distribution in other tissues, which indicated that microspheres could be an effective parenteral carrier for the delivery of BDMC in lung cancer treatment.
Safety of resuming anti-PD-1 in patients with immune-related adverse events (irAEs) during combined anti-CTLA-4 and anti-PD1 in metastatic melanoma
Authors: M.H. Pollack, A. Betof, H. Dearden, K. Rapazzo, I. Valentine, A.S. Brohl, K.K. Ancell, G.V. Long, A.M. Menzies, Z. Eroglu, D.B. Johnson, A.N. Shoushtari
Journal: Annals of Oncology (2017)